Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Income Statement [Abstract]        
Revenue $ 210
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 161
Research and development expenses (including non-cash share-based compensation expenses of $520, $771, $1,517 and $3,014, respectively) 1,088 1,445 3,154 5,018
General and administrative expenses (including non-cash share-based compensation expenses of $697, $675, $1,990 and $2,531, respectively) 1,756 1,352 4,855 5,248
Total operating costs and expenses 2,844 2,797 8,170 10,266
Loss from operations (2,844) (2,797) (7,960) (10,266)
Interest income 296 22 751 24
Net loss (2,548) (2,775) (7,209) (10,242)
Less: Net loss attributable to noncontrolling interest (37) (29) (88) (123)
Net loss attributable to common shareholders $ (2,511) $ (2,746) $ (7,121) $ (10,119)
Net loss per common share attributable to common shareholders:        
Basic $ (0.08) $ (0.09) $ (0.23) $ (0.33)
Diluted $ (0.08) $ (0.09) $ (0.23) $ (0.33)
Weighted average common shares outstanding:        
Basic 30,974 30,451 30,941 30,244
Diluted 30,974 30,451 30,941 30,244